Fungal infections in hematology patients: advances in prophylaxis and treatment Vincent CC Cheng MBBS (HK), MD (HK), PDipID (HK), MCRP (UK), FRCPath (UK), FHKCPath, FHKAM (Path) Department of Microbiology Queen Mary Hospital ASIA-PACIFIC HEMATOLOGY CONSORTIUM
31
Embed
Fungal infections in hematology patients: advances in prophylaxis and treatment
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Fungal infections in hematology patients: advances in prophylaxis and treatment
Vincent CC Cheng MBBS (HK), MD (HK), PDipID (HK), MCRP (UK), FRCPath (UK),
FHKCPath, FHKAM (Path) Department of Microbiology
Queen Mary Hospital
ASIA-PACIFIC HEMATOLOGY CONSORTIUM
Mortality from invasive fungal infection in patients with acute leukemia and HSCT
(40-50%) (>70%)
Halo sign:
Nodular lesion surrounded by an area of ground-grass attenuation
Air crescent sign: Nodular lesion with internal necrotic cavity
Degree of neutropenia, diagnosis, type of transplant, exposure to corticosteroids, type of chem
otherapy, and prior fungal colonization w
ere the major criteria used for stratification
High risk Prolong neutropenia (<0.1x109/L for 3 wk and / or <0.5x109/L for 5 wk) Allogeneic unrelated or mismatched BMT GVHD High dose Arabinose-C Corticosteroids > 1/mg/kg with neutropenia <0.1x109/L over 1 wk Corticosteroids > 2 mg/kg over 2 wk Intermediate risk (high intermediate) Fungal colonization at 1 site with neutropenia 0.1-0.5x109/L for 3-5 wk Fungal colonization at > 1 site AML Total body irradiation Allogeneic matched sibling donor BMT Intermediate risk (low intermediate) Neutropenia 0.1-0.5x109/L < 3 wk Antibiotics + lymphopenia <0.5x109/L Older age Presence of a central venous catheter
Low risk Autologous BMT Lymphoma Childhood AML
Risk group Prophylaxis Pre-emptive Empirical Targeted High Yes Yes Yes Intermediate (high)
Yes Yes Yes
Intermediate (low)
Yes ? Yes
Low Yes ? Yes
Risk Based approach in antifungal treatment
Degree of neutropenia, diagnosis, type of transplant, exposure to corticosteroids, type of chemotherapy, and
prior fungal colonization were the major criteria used for stratification
Br J Haematol. 2000 Aug;110(2):273-84.
Selected antifungal prophylaxis trials with > 100 patients with hematologic malignancies and Hematopoietic cell transplant Study Patients Design Regimen Outcome
Fluconazole
Goodman et al (1992)
356 (allo/ auto BMT)
RCT (double blinded)
FLU 400 mg qd po vs placebo
IFI: FLU ↓ Mortality: FLU ↓
Winston et al (1993)
257 acute leukemia patients on chemo
RCT (double blinded)
FLU 400 mg qd po or 200 mg bd iv vs placebo
IFI: No diff (3 cases of Aspergillus in both arms) Mortality: no diff
Slavin et al (1995)
300 (allo/ auto BMT)
RCT (double blinded)
FLU 400mg qd po vs placebo
IFI: FLU ↓ Mortality: FLU ↓
Rotstein et al (1999)
304 (44% auto BMT)
RCT (double blinded)
FLU 400mg qd po vs placebo
IFI: FLU ↓ Mortality: FLU ↓
Goodman JL, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326 (13): 845-851. Winston DJ, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia: results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993; 7 (118): 495-503. Slavin MA, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation : a prospective, randomized, double-blind study. J Infect Dis 1995; 171 (6): 1545-1552. Rotstein C, et al. Randomized placebo controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 1999; 28 (2): 331-340.
Selected antifungal prophylaxis trials with > 100 patients with hematologic malignancies and Hematopoietic cell transplant Study Patients Design Regimen Outcome
Itraconazole
Morgenstern et al (1999)
445 (includes autologous and BMT) & HM patients
Open-label
ITR 2.5 mg/kg cyclodextrin solution bd po vs FLU 100 mg suspension qd po
IFI: No diff Mortality: ITR ↓
Huijgen et al (1999)
213 patients (57% auto BMT; 31% HM on chemo
RCT (double blinded)
ITR 100 mg bd po vs FLU 50 mg bd po
IFI: No diff Mortality: no diff
Harousseau et al (2000)
557 HM patients (5% BMT)
RCT (double blinded)
ITR 2.5 mg/kg solution bd po vs AMB 500 mg capsule qid po
IFI: No diff Mortality: No diff
Marr et al (2004)
304 (allo BMT) Open-label
ITR 2.5 mg/kg solution td po or 200 mg iv qd vs FLU 400 mg po or iv qd
IFI: ITR ↓ Mortality: No diff
Morgenstern GR, et al. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological alignancies. Br J Haematol 1999; 105 (4): 901-911. Huijgens PC, et al. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. J Clin Pathol 1999; 52 (5): 376-380. Harousseau JL, et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 2000; 44 (7): 1887-1893. Marr KA, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103 (4): 1527-1533.
Selected antifungal prophylaxis trials with > 100 patients with hematologic malignancies and Hematopoietic cell transplant
Study Patients Design Regimen Outcome
Posaconazole
Ullmann et al (2007)
600 (allo BMT) RCT (double blinded)
POS 200 mg suspension td po vs FLU 400 mg qd po
IFI: POS ↓ Mortality: POS ↓
Cornely at al (2007)
602 AML or MDS patients on chemotherapy
RCT (evaluator blinded)
POS 200 mg suspension td po vs FLU 400 mg suspension qd po or ITR 200 mg solution bd po
IFI: POS ↓ Mortality: POS ↓
Micafungin
van Burik et al (2004)
889 (46% auto BMT, 54% Allo BMT)
RCT (double blinded)
MICA 50 mg iv qd vs FLU 400 mg iv qd
IFI: MICA↓ Mortality: No diff
Ullmann AJ, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356 (4): 335-347. Cornely OA, et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356 (4): 348-359. van Burik JA, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39 (10): 1407-1416.
A randomized, double-blind trial comparing voriconazole (200 mg twice daily) vs fluconazole (400 mg daily) in allograft recipients >2 years of age considered to be at standard risk of IFI
Prophylaxis: at least 100 days extended to 180 days if receiving prednisone (>1 mg/kg daily) and/or CD4 cells <200/µL Serum galactomannan levels & intensive diagnostic process Fungal-free survival: 78% with voriconazole (6 mo) 75% with fluconazole (6 mo) 64% with voriconazole (12 mo) 65% with fluconazole (12 mo)
Wingard JR, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010; 116: 5111–5118.
Marks DI, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic stem cell transplanation. Br J Haematol 2011; 155: 318–327.
A prospective, phase III, randomized, open label, multi-centre clinical trial Eligible patients: >12 years of age allogeneic HCT for acute leukaemia, transformed CML, or failure of lymphoma therapy
Prophylaxis : at least 100 days antifungal continued until 80 days if IFI risk factors persisted Primary endpoint: Success of antifungal prophylaxis at day 180 (defined as fungal-free survival to day 180 without having discontinued study treatment for >14 days in total before day 100) Survival outcome at Day 100, 180, and 1 year (no difference)
Maertens J, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3 – 2009 update. Bone Marrow Transplant 2011; 46: 709–718.
Patient risk stratification and treatment recommendations for primary antifungal prophylaxis in haematology patients as per the ECIL-3 (3rd European Conference on Infections in Leukemia) guidelines
Serum drug concentrations of posaconazole and itraconazole be monitored to ensure therapeutic levels of these agents
Empirical antifungal therapy: • Targets haematology patients that have prolonged neutropenia • Persistent or relapsing fever despite 4–7 days of adequate broad spectrum
antibiotics • Absence of other clinical symptoms/signs, conventional radiological and laboratory findings specific investigations aimed at documenting invasive fungal disease (e.g. CT scan, detection of circulating fungal markers) • Based on moderate evidence from clinical trials with small sample size and
debatable methodology/design
• May results in significant overtreatment, toxicity and expenditure
Klastersky J. Antifungal therapy in patientswith fever and neutropenia—more rational and less empirical? N Engl J Med 2004; 351: 1445–7.
N Engl J Med. 2004 Sep 30;351(14):1445-7.
Measures of the Success of Empirical Antifungal Therapy with Conventional or Liposomal Amphotericin B, Voriconazole, or Caspofungin
Walsh TJ, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999;340:764-71. Walsh TJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346:225-34. Walsh TJ, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391-402.
Liposomal Ampho B vs Ampho B deoxycholate Liposomal Ampho B vs Voriconazole Caspofungin vs Liposomal Ampho B
Bone Marrow Transplant 2011; 46: 709–718.
ECIL 3 guidelines on empirical antifungal treatment in neutropenic patients with persistent or relapsing fever
The time period between fungal replication, invasion and appearance of signs and symptoms represents a window of opportunity for earlier treatment. However, there is as yet no consensus definition of preemptive antifungal therapy. Such therapy should not be triggered by fever as a sole criterion, but should rest on: (i) a clear identification of those patients who are at risk of fungal disease (ii) utilization of sensitive techniques that facilitate rapid and early diagnosis of
invasive mould infections, e.g. galactomannan, b-D-glucan or PCR testing as well as computerized radiological imaging techniques
• Biweekly testing may allow earlier detection of IA
• With the cutoff OD index reduced to 0.5 (from 1.5), greater overall sensitivity improved from 76% to 97%
• High percentage of false positives; sensitivity 100%-33%
• Exposure to mold-active antifungals considerably reduces sensitivity
• Some serum reactivity in patients on beta-lactam antibiotics
(1, 3)-beta-Dglucan antigen test
• Noninvasive serum assay • Detects Candida and
Aspergillus species and other opportunistic fungal pathogens
• False-positive and false-negative
• Sensitivity lower in patients with localized Aspergillus infection
• Does not usually detect Cryptococcus species or Zygomycetes
PCR assays • Highly specific and sensitive • Negative result can rule out IA
and potentially limits empiric therapy need
• No pan-fungal assay available to date
• Lack of a standardized method
Eur J Haematol. 2011 Oct;87(4):289-301.
Advantages and disadvantages of major non-culture-based laboratory diagnostic methods for IFI
Clin Infect Dis. 2005 Nov 1;41(9):1242-50.
liposomal amphotericin B
Fever-driven approach: Antifungal Rx: 41 of 136 episodes Pre-emptive approach: Antifungal Rx <25% episodes (but identified 10 episodes of fungal infection without fever or with the presence of confounding febrile conditions) No patient received mould-active prophylaxis (? improving the sensitivity of the assay and favoring the pre-emptive approach)
Clin Infect Dis. 2009 Apr 15;48(8):1042-51.
293 patients with haematological malignancies (duration of neutropenia ≥ 10 days) 17 patients developed an IFI: 4 (2.7%) in empirical group 13 (9%) in pre-emptive group (P<0.02) Overall survival rates: 2 weeks after neutrophil recovery (95% vs 97%, P=0.12) Duration of neutropenia < 15 days: no difference Prolonged neutropenia: ↑risk of fungal infection in the pre-emptive therapy arm
Pre-emptive approach significantly reduced the use of antifungal agents (39.2% vs 61.3%, P<0.001)
Antifungal prophylaxis was given according to each center’s protocol Amphotericin B deoxycholate (1 mg/kg/day) Liposomal amphotericin (3 mg/kg/day)
Known pathogen therapy (Targeted therapy) of mould infections Voriconazole: first-line therapy of invasive aspergillosis based on the results of a prospective, randomized clinical trial with amphotericin B deoxycholate as comparative initial therapy in possible, probable or proven disease 149 (54%) of 277 patients were culture +ve for Aspergillosis
Herbrecht R, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–15.
Potential concern of using voriconazole: prior exposure to mould-active azoles, the concomitant use of contraindicated medication (e.g. sirolimus), the risk of severe drug interactions, moderate to severe hepatic or renal impairment
Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327–60.
Treatment of aspergillosis: clinical practice guidelines of IDSA
Condition Primary Rx Alternative Rx
Invasive pulmonary aspergillosis Invasive sinus aspergillosis Tracheobronchial aspergillosis Chronic necrotizing pulmonary aspergillosis (subacute invasive pulmonary aspergillosis) Aspergillosis of the CNS
Voriconazole (6 mg/kg IV every 12 h for 1 day, followed by 4 mg/kg IV every 12 h; oral dosage is 200 mg every 12 h)
L-AMB (3–5 mg/kg/day IV), ABLC (5 mg/kg/day IV), Caspofungin (70 mg day 1 IV and 50 mg/day IV thereafter), Micafungin (IV 100–150 mg/day; dose not stablished), Posaconazole (200 mg QID initially, then 400 mg BID PO after stabilization of diseased), Itraconazole (dosage depends upon formulation)
Surgical debridement may be indicated
Known pathogen therapy (Targeted therapy) of mould infections
Echinocandins in the primary therapy of invasive aspergillosis: limited data non-comparative Phase II study in two different cohorts:
Viscoli C, et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009; 64: 1274–81. Herbrecht R, et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant 2010; 45: 1227–33.
Patients (HSCT or hemic malignancies) Pulmonary aspergillosis (proven or probable) Failure with amphotericin B
P=0.048
Observational study of salvage therapy
* historical control
Voriconazole Caspofungin
Antifungal treatment of other invasive mould infections
Fusarium and Scedosporium spp: Voriconazole and lipid formulations of amphotericin B +/-surgical debridement of necrotic tissue Posaconazole can be used as salvage therapy for these infections Invasive mucormycosis: Lipid-based formulation of amphotericin B as first-line therapy
Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007; 20: 695–704. Troke P, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother 2008; 52: 1743–50. Spellberg B, et al. Clinical practice: recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009; 48: 1743–51.